Ausgabe 3/2018
Inhalt (22 Artikel)
Cellular pharmacology studies of anticancer agents: recommendations from the EORTC-PAMM group
Paola Perego, Georg Hempel, Stig Linder, Tracey D. Bradshaw, Annette K. Larsen, Godefridus J. Peters, Roger M. Phillips
First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?
Shuyun Wang, Aiqin Gao, Jie Liu, Yuping Sun
Pharmacokinetics of dacarbazine (DTIC) in pregnancy
Ira Kantrowitz-Gordon, Karen Hays, Olumide Kayode, Aditya R. Kumar, Henry G. Kaplan, Joel M. Reid, Stephanie L. Safgren, Matthew M. Ames, Thomas R. Easterling, Mary F. Hebert
A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1202)
Hiroaki Yanagimoto, Hideyoshi Toyokawa, Daisuke Sakai, Hiroshi Wada, Sohei Satoi, Tomohisa Yamamoto, Hiroaki Nagano, Masanori Toyoda, Tetsuo Ajiki, Hironaga Satake, Akihito Tsuji, Atsushi Miyamoto, Masanori Tsujie, Shigekazu Takemura, Kazuhiro Yanagihara, Tatsuya Ioka
Rabdocoestin B exhibits antitumor activity by inducing G2/M phase arrest and apoptosis in esophageal squamous cell carcinoma
Jingnan Wang, Zhirong Zhang, Yun Che, Zuyang Yuan, Zhiliang Lu, Yuan Li, Jun Wan, Handong Sun, Zhaoli Chen, Jianxin Pu, Jie He
Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations
Nilsa Rivera-Del Valle, Tiewei Cheng, Mary E. Irwin, Hayley Donnella, Melissa M. Singh, Joya Chandra
The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer
Kathleen Moore, Zhi-Yi Zhang, Shefali Agarwal, Howard Burris, Manish R. Patel, Vikram Kansra
A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab
Francisco J. Esteva, Justin Stebbing, Rebecca N. Wood-Horrall, Peter J. Winkle, Sung Young Lee, Sang Joon Lee
Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83™, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach
Myrna Candelaria, Derlis Gonzalez, Francisco Javier Fernández Gómez, Alexandra Paravisini, Ana Del Campo García, Luis Pérez, Bernardo Miguel-Lillo, Susana Millán
Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors
John Nemunaitis, Annie Young, Samuel Ejadi, Wilson Miller, Lin-Chi Chen, Gwen Nichols, Steven Blotner, Faye Vazvaei, Jianguo Zhi, Albiruni Razak
Docetaxel, cisplatin and S-1 (DCS) combination chemotherapy for gastric cancer patients with peritoneal metastasis: a retrospective study
Hiroyuki Ohnuma, Yasushi Sato, Masahiro Hirakawa, Shohei Kikuchi, Koji Miyanishi, Tamotsu Sagawa, Yasuo Takahashi, Takayuki Nobuoka, Koichi Okamoto, Hiroshi Miyamoto, Ichiro Takemasa, Tetsuji Takayama, Junji Kato
Multicenter retrospective study of cetuximab plus platinum-based chemotherapy for recurrent or metastatic oral squamous cell carcinoma
Souichi Yanamoto, Masahiro Umeda, Mitomu Kioi, Tadaaki Kirita, Tetsuro Yamashita, Hiroyoshi Hiratsuka, Satoshi Yokoo, Hideki Tanzawa, Narikazu Uzawa, Takahiko Shibahara, Yoshihide Ota, Hiroshi Kurita, Masaya Okura, Hiroyuki Hamakawa, Jingo Kusukawa, Iwai Tohnai
2-Deoxy-d-glucose enhances TRAIL-induced apoptosis in human gastric cancer cells through downregulating JNK-mediated cytoprotective autophagy
Yuting Xu, Qingling Wang, Lin Zhang, Maojin Zheng
Long-term results of S-1 plus cisplatin with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer
Tetsuhiko Taira, Kiyotaka Yoh, Seisuke Nagase, Kaoru Kubota, Hironobu Ohmatsu, Seiji Niho, Masakatsu Onozawa, Tetsuo Akimoto, Yuichiro Ohe, Koichi Goto
S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma
Stine Braendegaard Winther, Jon Kroll Bjerregaard, Katrine Rahbek Schonnemann, Mathilde Weisz Ejlsmark, Merete Krogh, Helle Anita Jensen, Per Pfeiffer
Role of TPMT and ITPA variants in mercaptopurine disposition
Tina Gerbek, Maria Ebbesen, Jacob Nersting, Thomas L. Frandsen, Malin Lindqvist Appell, Kjeld Schmiegelow
A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies
John F. Deeken, Hongkun Wang, Marion Hartley, Amrita K. Cheema, Brandon Smaglo, Jimmy J. Hwang, Aiwu Ruth He, Louis M. Weiner, John L. Marshall, Giuseppe Giaccone, Stephen Liu, Jim Luecht, Jay Y. Spiegel, Michael J. Pishvaian
Phase 1 summary of plasma concentration–QTc analysis for idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors and AML
Steven Blotner, Lin-Chi Chen, Cristiano Ferlini, Jianguo Zhi
A phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline resectable pancreatic cancer
Jacob E. Shabason, Jerry Chen, Smith Apisarnthanarax, Nevena Damjanov, Bruce Giantonio, Arturo Loaiza-Bonilla, Peter J. O’Dwyer, Mark O’Hara, Kim A. Reiss, Ursina Teitelbaum, Paul Wissel, Jeffrey A. Drebin, Charles Vollmer, Michael Kochman, Rosemarie Mick, Norge Vergara, Nirag Jhala, Abigail Doucette, John N. Lukens, John P. Plastaras, James M. Metz, Edgar Ben-Josef
Vitamin D pathway gene polymorphisms and hepatocellular carcinoma in chronic hepatitis C-affected patients treated with new drugs
Jessica Cusato, Lucio Boglione, Amedeo De Nicolò, Fabio Favata, Alessandra Ariaudo, Simone Mornese Pinna, Federica Guido, Valeria Avataneo, Marco Cantù, Chiara Carcieri, Giuseppe Cariti, Giovanni Di Perri, Antonio D’Avolio
A note on improved statistical approaches to account for pseudoprogression
Nacer Abrouk, Bryan Oronsky, Scott Caroen, Shoucheng Ning, Susan Knox, Donna Peehl
Retraction Note to: Quinoxaline 1,4-dioxides induce G2/M cell cycle arrest and apoptosis in human colon cancer cells
Hala U. Gali-Muhtasib, Mona Diab-Assaf, Makhluf J. Haddadin